Addex Therapeutics (ADXN) Change in Receivables (2019 - 2025)

Addex Therapeutics has disclosed Change in Receivables across 7 years of filings, most recently posting $24.0 billion for Q2 2025.

• Change in Receivables for Q2 2025 came in at $24.0 billion, up 268.43% year-over-year; the trailing twelve-month figure through Jun 2025 was -$2.8 billion (up 98.45% YoY), and the FY2025 annual result was -$5516.8, down 105.19% from the prior year.
• Change in Receivables came in at $24.0 billion for Q2 2025 at Addex Therapeutics, up from -$22.1 billion in the prior quarter.
• In the past five years, Change in Receivables ranged from a high of $423.9 billion in Q4 2024 to a low of -$428.7 billion in Q3 2024.
• The 5-year median for Change in Receivables is $15006.1 (2021), against an average of -$286.2 million.
• Peak annual rise in Change in Receivables reached 492631036.91% in 2023, while the deepest fall reached 211928263.42% in 2023.
• Addex Therapeutics' Change in Receivables stood at $37144.2 in 2021, then plunged by 433.12% to -$123736.4 in 2022, then sank by 211928263.42% to -$262.2 billion in 2023, then surged by 261.67% to $423.9 billion in 2024, then slumped by 94.34% to $24.0 billion in 2025.
• The last three Change in Receivables figures came in at $24.0 billion (Q2 2025), -$22.1 billion (Q1 2025), and $423.9 billion (Q4 2024), per Business Quant data.